There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Investor's Business Daily on MSN
Eli Lilly stock hovers in buy zone, finds key support amid $3 billion deal
Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.
I n 1876 Eli Lilly, a veteran of the civil war, founded a company in Indianapolis to bring scientific rigour to a medicines ...
Novo Nordisk is finally getting one up on its biggest rival.
Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have ...
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish ...
With a share price of $1,182, Eli Lilly (LLY) is positioned for about 76% potential growth over the next three years in a ...
The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results